Stock listing
NASDAQ:KLRA Kailera Therapeutics, Inc. Stock
Home listing (NASDAQ) of Kailera Therapeutics, Inc.
Follow Kailera Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:KLRA
$11.02 USD -0.77 (-6.5%)
Close on Nov 20, 2026
- Day range
- $11.00 – $11.87 USDNov 20, 2026
- Volume
- 553,229 sharesNov 20, 2026
- Market cap
- $1.43B USDAt the close on Nov 20, 2026 · price × 129.9M shares outstanding
- Traded on an average day
- $13.73M USDMedian day 962,425 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KLRA · Home | $11.02 USD | -0.77 (-6.5%) | 553,229 | $11.29 | $11.87 | $11.00 | $11.79 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KLRA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $11.02 | -0.77 | -6.5% | $11.29 | $11.87 | $11.00 | 553,229 | |
| $11.79 | -0.41 | -3.4% | $12.28 | $12.51 | $11.79 | 418,798 | |
| $12.20 | -0.37 | -2.9% | $12.46 | $12.68 | $11.86 | 510,056 | |
| $12.57 | -0.70 | -5.3% | $12.91 | $13.31 | $12.47 | 962,425 | |
| $13.27 | +0.06 | +0.5% | $13.21 | $13.62 | $12.78 | 536,741 | |
| $13.21 | -1.17 | -8.1% | $14.31 | $14.31 | $13.19 | 563,116 | |
| $14.38 | +0.14 | +1.0% | $14.30 | $14.62 | $14.00 | 609,999 | |
| $14.24 | +0.54 | +3.9% | $13.72 | $14.89 | $13.39 | 1,182,697 | |
| $13.70 | +0.73 | +5.6% | $13.42 | $14.33 | $13.01 | 1,366,417 | |
| $12.97 | +0.80 | +6.6% | $12.29 | $13.26 | $11.97 | 733,038 | |
| $12.17 | -0.63 | -4.9% | $13.30 | $13.30 | $11.93 | 842,152 | |
| $12.80 | +0.22 | +1.7% | $13.02 | $13.19 | $12.15 | 651,264 | |
| $12.58 | +0.43 | +3.5% | $12.32 | $12.99 | $12.30 | 775,937 | |
| $12.15 | -0.71 | -5.5% | $12.94 | $13.02 | $11.96 | 881,410 | |
| $12.86 | -0.55 | -4.1% | $13.27 | $13.40 | $12.54 | 868,347 | |
| $13.41 | -0.01 | -0.1% | $13.49 | $13.83 | $13.30 | 1,037,482 | |
| $13.42 | +0.29 | +2.2% | $13.04 | $13.44 | $12.73 | 876,003 | |
| $13.13 | +0.36 | +2.8% | $12.94 | $13.27 | $12.56 | 841,655 | |
| $12.77 | -0.08 | -0.6% | $12.85 | $13.14 | $12.62 | 588,890 | |
| $12.85 | -0.42 | -3.2% | $13.18 | $13.18 | $12.46 | 1,560,600 | |
| $13.27 | +0.35 | +2.7% | $12.80 | $13.34 | $12.56 | 855,500 | |
| $12.92 | +0.03 | +0.2% | $12.91 | $13.22 | $12.70 | 1,282,800 | |
| $12.89 | +1.46 | +12.8% | $11.43 | $13.06 | $11.43 | 1,580,000 | |
| $11.43 | +0.18 | +1.6% | $11.34 | $11.69 | $11.18 | 896,600 | |
| $11.25 | -0.46 | -3.9% | $11.75 | $11.79 | $11.16 | 1,299,400 | |
| $11.71 | +0.97 | +9.0% | $10.61 | $11.76 | $10.50 | 1,174,300 | |
| $10.74 | -0.03 | -0.3% | $10.64 | $10.99 | $10.44 | 1,304,800 | |
| $10.77 | -0.56 | -4.9% | $11.31 | $11.44 | $10.72 | 1,106,600 | |
| $11.33 | -0.28 | -2.4% | $11.39 | $11.70 | $10.98 | 1,220,400 | |
| $11.61 | +1.61 | +16.1% | $10.13 | $11.81 | $9.98 | 2,181,200 | |
| $10.00 | -0.53 | -5.0% | $10.42 | $10.42 | $9.76 | 1,532,200 | |
| $10.53 | -0.30 | -2.8% | $10.77 | $11.12 | $10.50 | 1,091,700 | |
| $10.83 | -0.01 | -0.1% | $10.95 | $11.24 | $10.32 | 1,452,000 | |
| $10.84 | +0.45 | +4.3% | $10.48 | $11.04 | $9.85 | 1,811,900 | |
| $10.39 | -0.64 | -5.8% | $11.23 | $11.40 | $10.29 | 1,280,900 | |
| $11.03 | -0.39 | -3.4% | $11.39 | $11.76 | $10.57 | 2,187,200 | |
| $11.42 | +0.43 | +3.9% | $11.16 | $11.67 | $10.86 | 1,368,800 | |
| $10.99 | -0.13 | -1.2% | $11.10 | $11.31 | $10.83 | 694,100 | |
| $11.12 | -0.10 | -0.9% | $11.30 | $11.52 | $11.07 | 1,433,500 | |
| $11.22 | -0.76 | -6.3% | $11.80 | $12.33 | $11.10 | 1,722,600 | |
| $11.98 | -1.15 | -8.8% | $12.85 | $13.12 | $11.77 | 2,761,200 | |
| $13.13 | +0.34 | +2.7% | $12.76 | $13.22 | $12.56 | 1,631,800 | |
| $12.79 | +0.80 | +6.7% | $12.46 | $12.95 | $12.05 | 1,230,000 | |
| $11.99 | -0.84 | -6.5% | $12.95 | $13.04 | $11.84 | 1,050,200 | |
| $12.83 | -0.09 | -0.7% | $12.98 | $13.23 | $12.36 | 3,164,400 | |
| $12.92 | +0.22 | +1.7% | $13.07 | $13.21 | $12.63 | 1,036,200 | |
| $12.70 | -0.75 | -5.6% | $13.55 | $13.68 | $12.47 | 1,134,500 | |
| $13.45 | -0.30 | -2.2% | $13.71 | $13.98 | $13.32 | 726,400 | |
| $13.75 | -0.19 | -1.4% | $13.91 | $14.12 | $13.56 | 872,400 | |
| $13.94 | -0.97 | -6.5% | $15.10 | $15.40 | $13.90 | 815,400 | |
| $14.91 | +0.07 | +0.5% | $14.58 | $14.98 | $14.51 | 661,400 | |
| $14.84 | -1.59 | -9.7% | $16.27 | $16.32 | $14.76 | 743,700 | |
| $16.43 | +0.20 | +1.2% | $15.79 | $16.63 | $15.62 | 1,000,500 | |
| $16.23 | +0.49 | +3.1% | $15.60 | $16.44 | $15.57 | 523,300 | |
| $15.74 | -0.11 | -0.7% | $15.95 | $16.51 | $15.50 | 642,500 | |
| $15.85 | -0.56 | -3.4% | $16.39 | $16.82 | $15.59 | 737,300 | |
| $16.41 | +1.01 | +6.6% | $15.21 | $17.06 | $15.15 | 1,200,800 | |
| $15.40 | -0.81 | -5.0% | $16.26 | $16.64 | $15.15 | 1,144,000 | |
| $16.21 | -2.32 | -12.5% | $18.26 | $18.26 | $16.19 | 532,000 | |
| $18.53 | +0.09 | +0.5% | $18.31 | $18.78 | $17.76 | 439,600 | |
| $18.44 | +0.69 | +3.9% | $17.71 | $18.47 | $17.37 | 785,300 | |
| $17.75 | +1.21 | +7.3% | $16.75 | $18.19 | $16.54 | 1,323,874 | |
| $16.54 | -0.63 | -3.7% | $17.14 | $17.16 | $16.37 | 549,546 | |
| $17.17 | -0.29 | -1.7% | $17.52 | $17.96 | $17.00 | 436,800 | |
| $17.46 | -0.86 | -4.7% | $18.20 | $18.37 | $17.17 | 544,900 |
- Ticker
- NASDAQ:KLRA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Kailera Therapeutics to Present at ObesityWeek 2026
Latest deck · September 2026
Technical Presentation (September 2026)
Technical · 19 slides
Latest news
Kailera Therapeutics to Present at ObesityWeek 2026
Nov 10, 2026
Closed $14.24 (+3.9%) on Nov 10, 2026
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 4, 2026
Closed $12.17 (-4.9%) on Nov 5, 2026
Kailera Therapeutics to Participate in November Investor Conferences
Nov 3, 2026
Closed $12.58 (+3.5%) on Nov 3, 2026
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Oct 1, 2026
Closed $11.03 (-3.4%) on Oct 1, 2026
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
Sep 30, 2026
Closed $11.42 (+3.9%) on Sep 30, 2026
Kailera Therapeutics to Participate in September Investor Conferences
Sep 16, 2026
Closed $12.70 (-5.6%) on Sep 16, 2026
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 12, 2026
Closed $17.97 (-3.3%) on Aug 13, 2026
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Aug 11, 2026
Closed $18.87 (-0.6%) on Aug 11, 2026
Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
Jul 7, 2026
Closed $22.24 (-4.5%) on Jul 7, 2026
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Jun 29, 2026
Closed $21.67 (+4.0%) on Jun 29, 2026
Kailera Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 15 in all · newest Nov 10, 2026 · oldest 2026
- Decks
- 5 decks · latest September 2026
Where Kailera Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KLRA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KLRA | BOATS | United States | USD |
Valuation
Price/book 1.4× against a median of 2.5×: 2nd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $539.5M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.28
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| PELL Bio-Med Technology Co Ltd · TWSE:6949 | US$1.46B | US$1.40B | n/a | 1,591× | n/a | 18.7× | n/a | 0.1× | n/a |
| Mesoblast Limited · ASX:MSB | US$1.46B | US$1.42B | n/a | 82.4× | n/a | 2.4× | −593.9% | 0.2× | n/a |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.40B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Damora Therapeutics, Inc. · NASDAQ:DMRA | US$1.44B | US$910.0M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 0.88 |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| LigaChem Biosciences Inc. · KRX:141080 | US$1.43B | US$1.15B | n/a | 15.5× | n/a | 4.8× | −180.9% | 0.0× | n/a |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX | US$1.42B | US$521.8M | n/a | 77.6× | n/a | 2.5× | n/a | 0.0× | n/a |
| Nurix Therapeutics, Inc. · NASDAQ:NRIX | US$1.40B | US$683.6M | 4.8× | 1.0× | n/a | 1.4× | 42.0% | 0.0× | 1.15 |
| Intellia Therapeutics, Inc. · NASDAQ:NTLA | US$1.40B | US$1.00B | n/a | 19.0× | n/a | 2.3× | −805.7% | 0.1× | 2.01 |
| Median of the others | US$1.43B | US$1.11B | 4.8× | 17.2× | 2.5× | −121.0% | 0.1× | 1.70 |
Forecasts
6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 43.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.13 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ron Renaud | President & Chief Executive Officer |
| Doug Pagán | Chief Financial Officer |
| Paul Burgess | Chief Operating Officer & Chief Business Officer |
| Scott Akamine | Chief Legal Officer |
| Maura Gavaghan | Vice President, Investor Relations |
| Anna Robinson | Vice President, Communications |
| Jamie Coleman | Chief Commercial Officer |
| Kathleen Tregoning | Chief Corporate Affairs Officer |
| Martin Mackay | Co-Founder and Chair of Board, Rallybio Corporation |
| Nur Nicholson | Chief Technology Officer |
| Paula Cloghessy | Chief People Officer |
| Scott Wasserman | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| John F. Milligan | Board Chair |
| Martin Mackay | Co-Founder and Chair of Board, Rallybio Corporation |
| Adam Koppel | Partner, Bain Capital Life Sciences |
| Andrew Kaplan | Partner, Bain Capital Private Equity |
| Christopher Hite | Independent Board Member |
| Frank K. Clyburn | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −4.9% |
| Q2 2026 | Aug 12, 2026 · After close | −3.3% |
| Q1 2026 | May 26, 2026 · After close | +1.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2026) | Technical | 19 slides | September 2026 |
| Technical Presentation (September 2026) | Technical | 6 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 38 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 40 slides | May 2026 |
| Technical Presentation (September 2024) | Technical | 12 slides | September 2024 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$718.8M raised · US$16 a share · J.P. Morgan +5 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Leerink Partners (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), William Blair | Apr 20, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Apr 16, 2026.
- Price
- US$16.00 a share
- Shares offered
- 39,062,500 shares of common stock
- Offering size
- US$625 million
- Underwriters' option
- Up to 5,859,375 more shares
- Listing
- KLRA on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI, William Blair · In the order on the cover
- Shares delivered
- On or about Apr 20, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 19, 2025 |
| Filed publicly | Mar 27, 2026 |
| Amended once | Apr 13, 2026 |
| Shares registered with an exchange | Apr 14, 2026 |
| Declared effective by the SEC | Apr 16, 2026 |
| Final prospectus, with the price | Apr 17, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Apr 17, 2026 |
| EFFECT · Notice that a registration is effective | Apr 16, 2026 |
| S-1MEF · Registration of more shares for the same offering | Apr 16, 2026 |
| CERT · Exchange's certificate of listing | Apr 15, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 14, 2026 |
| S-1/A · Registration statement, amended | Apr 13, 2026 |
| S-1 · Registration statement | Mar 27, 2026 |
| DRS/A · Draft registration statement, amended | Feb 11, 2026 |
| DRS · Draft registration statement | Dec 19, 2025 |
Open IPO · From the cover of the final prospectus (424B4) filed Apr 17, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 |
|---|---|
| Revenue | 0 |
| Research and development | 109.1M |
| Selling, general and administrative | 49.2M |
| Operating income | -158.3M |
| Depreciation and amortization | 310.0K |
| EBITDA | -158.0M |
| Income before tax | -149.0M |
| Net income | -149.0M |
| Earnings per share, basic | -1.26 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 160.3M | 175.2M |
| Short-term investments | 385.8M | 0 |
| Receivables | 2.73M | |
| Current assets | 557.5M | 177.6M |
| Total assets | 692.3M | 178.4M |
| Accounts payable | 7.53M | 2.01M |
| Current liabilities | 46.4M | 6.91M |
| Total debt | 10.8M | |
| Total liabilities | 1.05B | 397.2M |
| Shareholders' equity | -356.5M | -218.8M |
| Shares outstanding | 117.9M | 117.9M |
Cash flow
| Line | FY2025 |
|---|---|
| Cash from operations | -120.2M |
| Capital spending | -2.09M |
| Free cash flow | -122.3M |
| Cash from investing | -492.6M |
| Cash from financing | 598.7M |
| Change in cash | -14.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
All 64 filings
Cap table
Built by 6ix from Kailera Therapeutics, Inc.’s releases · as of Oct 29, 2026
- Common shares
- 129,850,481
- Fully diluted
- 129,850,481
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 129,850,481 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 129,850,481 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Martin Mackay Other companies: SpringWorks Therapeutics Inc (Director · Since at least Jul 29, 2024); Rallybio Corporation (Director · Since at least Jul 28, 2021); Charles River Laboratories International, Inc. (Director · Since at least Jul 1, 2017); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & Global Head of R&D · May 13, 2013 – Feb 27, 2017 · Past); Pfizer, Inc. (Senior Vice President · Sep 30, 2008 – May 14, 2010 · Past) | Director · Since at least Apr 16, 2026 |
| Doug Pagán Other companies: Dicerna Pharmaceuticals Inc (Chief Financial Officer · May 26, 2020 – Dec 28, 2021 · Past); Alaunos Therapeutics, Inc. (Director · Sep 18, 2018 – Dec 31, 2019 · Past); Paratek Pharmaceuticals Inc (Chief Financial Officer · Dec 18, 2014 – Apr 5, 2019 · Past) | Chief Financial Officer · Since at least Apr 16, 2026 |
| John F. Milligan Other companies: 4D Molecular Therapeutics, Inc. (Executive Chairman · Since at least Dec 10, 2020); Pacific Biosciences of California, Inc. (Chairman of the Board · Since at least Jul 17, 2013); Gilead Sciences, Inc. (President and CEO, Director · Nov 7, 2013 – Nov 27, 2018 · Past) | Board Chair · Since at least Apr 16, 2026 |
| Kathleen Tregoning Other companies: COMPASS Pathways Plc (Director · Since at least May 27, 2026); Spero Therapeutics, Inc. (Director · Since at least Jun 12, 2025) | Chief Corporate Affairs Officer · Since at least Jun 29, 2026 |
| Paul Burgess Other companies: Cerevel Therapeutics Holdings Inc (See Remarks · Jun 20, 2023 – Aug 1, 2024 · Past); Translate Bio Inc (General Counsel and Secretary · Jun 27, 2018 – Jun 27, 2018 · Past) | Chief Operating Officer & Chief Business Officer · Since at least Apr 16, 2026 |
| Nur Nicholson Other companies: Apellis Pharmaceuticals, Inc. (Chief Technical Officer · Since at least Sep 25, 2020) | Chief Technology Officer · Since at least Aug 11, 2026 |
| Adam Koppel | Director · Since at least Apr 20, 2026 |
| Andrew Kaplan | Director · Since at least Apr 20, 2026 |
| Anna Robinson | Vice President, Communications · Since at least Nov 3, 2026 |
| Christopher Hite | Independent Board Member · Since at least Nov 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Frank K. Clyburn | Director · Since at least Nov 5, 2026 |
| Jamie Coleman | Chief Commercial Officer · Since at least Nov 5, 2026 |
| Martin Mackay | Co-Founder and Chair of Board, Rallybio Corporation · Since at least May 26, 2026 |
| Maura Gavaghan | Vice President, Investor Relations · Since at least Nov 3, 2026 |
| Paula Cloghessy | Chief People Officer · Since at least Apr 16, 2026 |
| Ronald C Renaud Jr | CEO & President, Director · Since at least Jun 9, 2026 |
| Ron Renaud | President & Chief Executive Officer · Since at least Jun 11, 2026 |
| Scott Akamine | Chief Legal Officer · Since at least Apr 16, 2026 |
| Scott Wasserman | Chief Medical Officer · Since at least Sep 30, 2026 |
| Yuting Liu | Director · Since at least Apr 16, 2026 |
Log in to ask 6ix AI your own questions about Kailera Therapeutics, Inc.